This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Ebers, G. C Search for Related Content PubMed PubMed Citation Articles by Ebers, G. C Social Bookmarking                         What's this?

Natural history of primary progressive multiple sclerosis

Department of Clinical Neurology, Radcliffe Infirmary, University of Oxford, Woodstock Road, Oxford OX2 6HE, UK, george.ebers{at}clinical-neurology.oxford.ac.uk

The relationship of primary progressive multiple sclerosis (PPMS) to relapsing -remitting MS (RRMS) and secondary progressive MS (SPMS) remains unclear. Natural history data from a population-based cohort of patients with PPMS followed for approximately 25 years demonstrate remarkable similarities in the progressive phases of PPMS and SPMS. Immunogenetic and magnetic resonance imaging studies in large numbers of patients also fail to differentiate between the two MS categories. PPMS thus resembles SPMS without the relapses, although the two forms do differ with respect to sex ratio. A n unfavourable outcome in PPMS is predicted by rapid early progression of disability and involvement of three or more systems. Natural history studies provide information on likely long-term outcomes and can be used in the design and interpretation of clinical trials in PPMS. The evidence that PPMS is distinct remains weak.

Key Words: natural history • primary progressive multiple sclerosis

Multiple Sclerosis, Vol. 10, No. 3 suppl, S8-S15 (2004)
DOI: 10.1191/1352458504ms1025oa


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				Z. Khaleeli, D. R. Altmann, M. Cercignani, O. Ciccarelli, D. H. Miller, and A. J. Thompson Magnetization Transfer Ratio in Gray Matter: A Potential Surrogate Marker for Progression in Early Primary Progressive Multiple Sclerosis Arch Neurol, November 1, 2008; 65(11): 1454 - 1459. [Abstract] [Full Text] [PDF]

				M Gironi, F Martinelli-Boneschi, P Sacerdote, C Solaro, M Zaffaroni, R Cavarretta, L Moiola, S Bucello, M Radaelli, V Pilato, et al. A pilot trial of low-dose naltrexone in primary progressive multiple sclerosis Multiple Sclerosis, September 1, 2008; 14(8): 1076 - 1083. [Abstract] [PDF]

				H. Tremlett, D. Paty, and V. Devonshire The natural history of primary progressive MS in British Columbia, Canada Neurology, December 27, 2005; 65(12): 1919 - 1923. [Abstract] [Full Text] [PDF]

				J M Greer and M P Pender The presence of glutamic acid at positions 71 or 74 in pocket 4 of the HLA-DR{beta}1 chain is associated with the clinical course of multiple sclerosis J. Neurol. Neurosurg. Psychiatry, May 1, 2005; 76(5): 656 - 662. [Abstract] [Full Text] [PDF]